Zacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.16 Per Share

Equities analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to post earnings per share (EPS) of $0.16 for the current quarter, Zacks reports. Zero analysts have made estimates for AMAG Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.07) and the highest is $0.50. AMAG Pharmaceuticals posted earnings per share of $1.52 in the same quarter last year, which would indicate a negative year over year growth rate of 89.5%. The firm is scheduled to announce its next earnings report on Tuesday, February 13th.

On average, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($4.79) per share for the current year, with EPS estimates ranging from ($6.63) to ($1.43). For the next fiscal year, analysts forecast that the company will report earnings of ($2.68) per share, with EPS estimates ranging from ($6.91) to ($0.36). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%.

A number of brokerages have recently commented on AMAG. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “hold” rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Piper Jaffray Companies began coverage on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company. Finally, ValuEngine upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $21.00.

Shares of AMAG Pharmaceuticals (AMAG) traded up $0.60 during midday trading on Friday, hitting $13.85. 611,747 shares of the stock were exchanged, compared to its average volume of 761,297. The firm has a market capitalization of $510.88, a PE ratio of -2.28 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $25.20.

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its stake in AMAG Pharmaceuticals by 10.6% during the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after buying an additional 267,873 shares during the period. Dimensional Fund Advisors LP boosted its stake in AMAG Pharmaceuticals by 18.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares during the period. Gotham Asset Management LLC boosted its stake in AMAG Pharmaceuticals by 17.8% during the second quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock worth $14,721,000 after buying an additional 121,137 shares during the period. Renaissance Technologies LLC boosted its stake in AMAG Pharmaceuticals by 1.7% during the second quarter. Renaissance Technologies LLC now owns 778,800 shares of the specialty pharmaceutical company’s stock worth $14,330,000 after buying an additional 12,800 shares during the period. Finally, Prudential Financial Inc. boosted its stake in AMAG Pharmaceuticals by 35.7% during the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after buying an additional 190,660 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.16 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/20/zacks-analysts-expect-amag-pharmaceuticals-inc-amag-will-post-earnings-of-0-16-per-share.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply